Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BridgeBio Pharma Inc

BBIO
Current price
31.94 USD +1.23 USD (+4.01%)
Last closed 30.94 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 5 382 539 264 USD
Yield for 12 month +248.31 %
Week
Month
Year
BBIO
21.11.2021 - 28.11.2021

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California. Address: 421 Kipling Street, Palo Alto, CA, United States, 94301

Analytics

WallStreet Target Price

46.18 USD

P/E ratio

Dividend Yield

Current Year

+77 648 000 USD

Last Year

+69 716 000 USD

Current Quarter

+4 091 000 USD

Last Quarter

+1 641 000 USD

Current Year

+74 214 000 USD

Last Year

+66 602 000 USD

Current Quarter

+3 493 000 USD

Last Quarter

+1 042 000 USD

Key Figures BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -537 753 984 USD
Operating Margin TTM -3847.96 %
PE Ratio
Return On Assets TTM -49.17 %
PEG Ratio
Return On Equity TTM -1789.67 %
Wall Street Target Price 46.18 USD
Revenue TTM 9 428 000 USD
Book Value -6.94 USD
Revenue Per Share TTM 0.06 USD
Dividend Share
Quarterly Revenue Growth YOY 1110.4 %
Dividend Yield
Gross Profit TTM 74 214 000 USD
Earnings Share -3.91 USD
Diluted Eps TTM -3.91 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BBIO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 697.3171
Price Sales TTM 570.91
Enterprise Value EBITDA -12.2675
Price Book MRQ 123.6828

Financials BBIO

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BBIO

For 52 weeks

6.64 USD 36.36 USD
50 Day MA 26.98 USD
Shares Short Prior Month 15 927 907
200 Day MA 21.7 USD
Short Ratio 13.31
Shares Short 16 283 879
Short Percent 15.27 %